A new angiotensin-II-receptor blocker, CGP 48933: Local tolerance and effect on intraocular pressure. A pilot study

European Journal of Ophthalmology

Volumn 7, Issue 1, 1997, Pages 35-39

  Kaiser, H J ^a   Graf, T ^a   Krejci, G ^b   Mathis, G A ^c   Jauch, A ^c   Flammer, J ^a  

^a UNIVERSITY EYE CLINIC   (Switzerland)

^b Inst for Methods of Clin Testing   (Germany)

^c CIBA Vision   (Switzerland)

Author keywords

Angiotensin II receptor antagonist; Intraocular pressure; Local tolerance

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; VALSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; GLAUCOMA; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030889615     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067219700700107     Document Type: Article

References (16)

1. Dzau VJ. Significance of the vascular renin angiotensin pathway. Hypertension 1986; 8: 553-9.
2. Dzau VJ. Short- and long-term determinations of cardiovascular function and therapy. Contributions of circulating and tissue renin angiotensin system. J Cardiovasc Pharmacol 1989; 14 (suppl 4): S1-S5.
3. Sramek SJ, Wallow IHL, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system. Invest Ophthalmol Vis Sci 1992; 33; 1627-32.
4. Sramek SJ, Wallow IHL, Day RP, Ehrlich EN. Ocular renin-angiotensin: lmmunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci 1988; 29: 1749-52.
5. Ferrari-Dileo G, Ryan JW, Rockwood EJ, Davis EB, Anderson DR. Angiotensin-converting enzyme in bovine, feline, and human ocular tissue. Invest Ophthalmol Vis Sci 1988; 29: 876-81.
6. Danser J, Derkx F, Admiraal P, Deinum J, deJong P, Schalenkamp M. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
7. Ferrari-Dileo G, Davis EB; Anderson DR. Angiotensin binding sites in bovine and human retinal blood vessels, invest Ophthalmol Vis Sci 1987; 28: 1747-51.
8. Rockwood EJ, Fantes F, Davis EB, Anderson DR. The response of retinal vasculature to angiotensin. Invest Ophthalmol Vis Sci 1987; 28: 676-82.
9. Nyborg NCB, Nielsen PJ. Angiotensin-II contracts isolated human posterior ciliary arteries. Invest Ophthalmol Vis Sci 1990; 31: 2471-3.
10. Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin II binding receptors in retinal and optic nerve head blood vessels. Invest Ophthalmol Vis Sci 1991; 32: 21-6.
11. Lograno MD, Reibaldi A. Receptor-response in fresh human ciliary muscle. Br J Pharmacol 1986; 87: 379-85.
12. Meyer P, Flammer J, Lüscher Th. Local action of the renin angiotensin system in the porcine ophthalmic circulation. Invest Ophthalmol Vis Sei 1995; 36: 555-62.
13. Watkins RW, Baum T, Cedeno K, Smith EM, Yuen PH, Ahn HS, Barnett A. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. J Ocular Pharmacol 1987; 3: 295-307.
14. Constad WH, Fiore P. Samson C, Cinotti A. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol 1988; 105: 674-7.
15. Al-Sereiti MR, Turner P. Effect of captopril (an angiotensin-converting enzyme inhibitor) on intraocular pressure in healthy human volunteers. J Ocular Pharmacol 1989; 5: 1-5.
16. Timmermmans P, Benfield P, Chiu AT, Herblin WF, Wong PC. Smith. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221-35.